Research analysts covering Aptorum Group.
Recent press releases and 8-K filings for APM.
Aptorum Group Announces Registered Direct Offering
APM
M&A
- Aptorum Group Limited announced a registered direct offering for the purchase and sale of 1,000,000 Class A ordinary shares at a price of $2.00 per share.
- In a concurrent private placement, the company will issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of $2.00 per share.
- The gross proceeds from the offering are expected to be $2 million, with an additional potential $4 million if the unregistered warrants are fully exercised.
- The net proceeds, estimated at approximately US$1.725 million, are intended to fund expenses related to the previously announced merger agreement with DiamiR Biosciences Corp. and for general working capital.
- The offering closed on October 14, 2025.
Oct 16, 2025, 8:30 PM
DiamiR Biosciences Corp. Reports Q3 2025 Results and Merger Agreement with Aptorum Group Limited
APM
M&A
Earnings
New Projects/Investments
- DiamiR Biosciences Corp. reported a net loss of $(283,700) for the three months ended August 31, 2025, compared to $(176,275) for the same period in 2024.
- Total revenue for Q3 2025 was $99,878, entirely from service revenue, a decrease from $208,843 in grant revenue during the prior year period, as grant funding was exhausted in January 2025.
- In July 2025, DiamiR entered into a definitive merger agreement with Aptorum Group Limited, which, if completed, would result in DiamiR shareholders receiving shares of the surviving company. This merger activity contributed to a significant increase in general and administrative expenses to $509,630 for the quarter.
- DiamiR received CLEP Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH) in August 2025 and renewed key licenses and accreditations, enabling it to offer new testing services.
- Management believes its current capital is insufficient to fund operations for the next twelve months and will need to raise additional capital.
Oct 15, 2025, 9:00 PM
Aptorum Group Reports Reduced Net Loss, Announces Merger with DiamiR Biosciences, and Addresses Going Concern
APM
Earnings
M&A
Profit Warning
- Aptorum Group Limited reported a significantly reduced net loss of $(441,780) for the six months ended June 30, 2025, compared to $(2,643,796) for the same period in 2024, primarily driven by a substantial decrease in research and development expenses.
- The company entered into an Agreement and Plan of Merger with DiamiR Biosciences Corp. on July 14, 2025, with DiamiR stockholders expected to own approximately 70% and existing Aptorum shareholders 30% of the combined company, and the merger is anticipated to close in the fourth quarter 2025.
- Management has determined that conditions, including a net loss of $449,295, working capital of $1,998,298, and an accumulated deficit of $72,871,308 as of June 30, 2025, raise substantial doubt about the Company's ability to continue as a going concern within one year.
Oct 3, 2025, 8:31 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more